Literature DB >> 7954448

Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds.

S L Neuhausen1, C J Marshall.   

Abstract

BRCA1, a breast-ovarian cancer susceptibility gene which has been localized to 17q21, appears to be a tumor suppressor gene based on evidence from loss of heterozygosity (LOH) studies. We analyzed 14 ovarian and breast tumors from BRCA1 carriers and 1 sporadic breast tumor from 3 kindreds for 17q21 LOH. Thirteen of the 14 tumors from gene carriers exhibited LOH of the wild-type allele. Tumors from one gene carrier and the sporadic breast case did not exhibit any LOH in the region. There was loss of the wild-type allele from both maternally and paternally derived chromosomes, therefore excluding the possibility of genomic imprinting and providing further evidence that BRCA1 is a tumor suppressor. Three tumors showed interstitial LOH in the region, and thus established the utility of familial tumors in refining a region surrounding a tumor suppressor gene in a manner analogous to using genetic recombinants.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954448

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site.

Authors:  H Ruffner; W Jiang; A G Craig; T Hunter; I M Verma
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

2.  DNA damage response mediated through BRCA1.

Authors:  Eun Ryoung Jang; Jong-Soo Lee
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

3.  Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.

Authors:  Anosheh Afghahi; Kirsten M Timms; Shaveta Vinayak; Kristin C Jensen; Allison W Kurian; Robert W Carlson; Pei-Jen Chang; Elizabeth Schackmann; Anne-Renee Hartman; James M Ford; Melinda L Telli
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

4.  Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.

Authors:  F Durocher; P Tonin; D Shattuck-Eidens; M Skolnick; S A Narod; J Simard
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

5.  Mapping and conformational characterization of the DNA-binding region of the breast cancer susceptibility protein BRCA1.

Authors:  Riffat Naseem; Alice Sturdy; David Finch; Thomas Jowitt; Michelle Webb
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

6.  Analysis of BRCA1 involvement in breast cancer in Indian women.

Authors:  P H Pestonjamasp; I Mittra
Journal:  J Biosci       Date:  2000-03       Impact factor: 1.826

Review 7.  BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

Authors:  Amal Aly; Shridar Ganesan
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

8.  Common BRCA1 variants and transcriptional activation.

Authors:  A N Monteiro; A August; H Hanafusa
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

9.  Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.

Authors:  Vladimir M Moiseyenko; Nikita M Volkov; Evgeny N Suspistin; Grigoriy A Yanus; Aglaya G Iyevleva; Ekatherina Sh Kuligina; Alexandr V Togo; Alexandr V Kornilov; Alexandr O Ivantsov; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

10.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.